Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients.

Background: Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB‐PVI in a large cohort of overweight and obese patients from the 1STOP project. Methods: Fro...

Full description

Bibliographic Details
Published in:Pacing & Clinical Electrophysiology Vol. 44; no. 2; pp. 306 - 318
Main Authors: Malaspina, Daniele, Brasca, Francesco, Iacopino, Saverio, Arena, Giuseppe, Molon, Giulio, Pieragnoli, Paolo, Tondo, Claudio, Manfrin, Massimiliano, Rovaris, Giovanni, Verlato, Roberto, Dello Russo, Antonio, Startari, Umberto, Sgarito, Giuseppe, Perego, Giovanni Battista
Format: research tables/charts Journal Article
Published: Wiley-Blackwell Feb2021
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148723238&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 148723238
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01478389
        4F8
      jtl: Pacing & Clinical Electrophysiology
      issn: 01478389
      maglogo: Y
    pubinfo:
      dt: Feb2021
      vid: 44
      iid: 2
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        148723238
        148055496
        148723238
        148723238
        10.1111/pace.14149
        148723238
      ppf: 306
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients.
      aug:
        au:
          Malaspina, Daniele
          Brasca, Francesco
          Iacopino, Saverio
          Arena, Giuseppe
          Molon, Giulio
          Pieragnoli, Paolo
          Tondo, Claudio
          Manfrin, Massimiliano
          Rovaris, Giovanni
          Verlato, Roberto
          Dello Russo, Antonio
          Startari, Umberto
          Sgarito, Giuseppe
          Perego, Giovanni Battista
        affil: Department of Cardiology, ASST Santi Paolo e Carlo, Presidio Ospedaliero San Carlo Borromeo, Milano, Italy
      sug:
        subj:
          Cryosurgery Methods
          Atrial Fibrillation
          Pulmonary Veins Surgery
          Obesity
          Patient Safety Evaluation
          Outcome Assessment
          Human
          Male
          Female
          Middle Age
          Aged
          Comparative Studies
          Descriptive Statistics
          Body Mass Index
          Risk Assessment
          After Care
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB‐PVI in a large cohort of overweight and obese patients from the 1STOP project. Methods: From 2012 to 2018, 2048 patients with atrial fibrillation (AF) (70% male, 59 ± 11 years; 75% paroxysmal AF) underwent index CB‐PVI. The patient data were separated into three cohorts for statistical evaluation, including: normal weight (body mass index [BMI] < 25 kg/m2), overweight (BMI = 25‐30 kg/m2), and obese patients (BMI > 30 kg/m2). Results: Out of 2048 patients, 693 (34%) patients had a BMI < 25 and were deemed as normal. There were 944 (46%) patients categorized as overweight (BMI = 25‐30) and 411 (20%) as obese (BMI > 30). Overweight or obese patients were more often in persistent AF, had more frequently hypertension and diabetes, had higher CHA2DS2‐VASc score, and had a number of failed antiarrhythmic drug (AAD). Periprocedural complication rates were similar among the three cohorts. The 12‐month freedom from AF recurrence was 76.4% in the normal BMI group as compared to 79.2% in the overweight and 73.5% in the obese group (p =.35). However, 48% of overweight patients were on AAD treatment during the follow‐up. By multivariate analysis, BMI was not a predictor for AF recurrence following the index CB‐PVI. Conclusion: CB‐PVI in obese patients is a safe procedure. Increased BMI (either moderate or severe) does not seem to be associated with a worse outcome or to a different rate of AAD discontinuation at 12 months.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N